Doxorubicin

Generic Name: Doxorubicin

Brand Names: Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₁

CAS Number: 23214-92-8

Unique Ingredient Identifier: 80168379AG

Background: Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...

Indication: Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...

Associated Conditions: AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor

Associated Therapies: -

Clinical Trials

Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 33

Registration Number: NCT00000801

Locations: 🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸
San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸
San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California, United States

and more 4 locations

Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease

Phase 2

Completed

Conditions: HIV Infections
Hodgkin's Disease

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT00000626

Locations: 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States
🇺🇸
SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States
🇺🇸
The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States

and more 5 locations

A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma

Phase 1

Completed

Conditions: Sarcoma, Kaposi
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 72

Registration Number: NCT00000954

Locations: 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Ucsf Aids Crs, San Francisco, California, United States
🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States

and more 11 locations

A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma

Phase 1

Completed

Conditions: HIV Infections
Sarcoma, Kaposi

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00000681

Locations: 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
Pitt CRS, Pittsburgh, Pennsylvania, United States
🇺🇸
SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States

and more 2 locations

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: HIV Infections
Lymphoma, Non-Hodgkin

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 250

Registration Number: NCT00000658

Locations: 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Ucsf Aids Crs, San Francisco, California, United States

and more 19 locations

A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma

Phase 2

Completed

Conditions: Sarcoma, Kaposi
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT00000996

Locations: 🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸
San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California, United States

and more 9 locations

A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

Phase 1

Completed

Conditions: HIV Infections
Sarcoma, Kaposi

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT00000987

Locations: 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States

Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members

Not Applicable

Completed

Conditions: Lymphoma, Non-Hodgkin
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT00000703

Locations: 🇺🇸
Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States
🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸
Milton S Hershey Med Ctr, Hershey, Pennsylvania, United States

and more 11 locations

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT00000689

Locations: 🇺🇸
USC CRS, Los Angeles, California, United States

Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer

Phase 2

Conditions: Breast Cancer

First Posted Date: 2000-11-06

Last Posted Date: 2005-06-24

Lead Sponsor: National Center for Research Resources (NCRR)

Registration Number: NCT00006433

Locations: 🇺🇸
Radiation Oncology, Duke University Medical Center, Durham, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy